Particle.news
Download on the App Store
3 ARTICLES
·
10mo ago

Pfizer Advances Daily Weight Loss Pill Amid FDA Rejection of Novo's Insulin

The FDA's decision impacts Novo Nordisk's weekly insulin, while Pfizer's new GLP-1 pill shows promise in weight management.

Ozempic Insulin injection pen or insulin cartridge pen for diabetics. Medical equipment for diabetes parients. C Insulin injection pen or insulin cartridge pen for diabetics.
Image
Image

Overview

  • Pfizer is developing a once-daily weight loss pill, danuglipron, aiming to compete in the GLP-1 space.
  • The FDA rejected Novo Nordisk's application for its once-weekly insulin icodec, citing concerns over manufacturing and safety.
  • The FTC report highlights that pharmacy benefit managers are driving up drug prices, leading to planned lawsuits.
  • Eli Lilly's diabetes and weight loss drugs are outperforming Novo Nordisk's medications in recent studies.
  • Eli Lilly is set to acquire Morphic for $3.2 billion, expanding its portfolio in inflammatory bowel disease treatments.